These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27138177)

  • 1. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
    Yu RZ; Graham MJ; Post N; Riney S; Zanardi T; Hall S; Burkey J; Shemesh CS; Prakash TP; Seth PP; Swayze EE; Geary RS; Wang Y; Henry S
    Mol Ther Nucleic Acids; 2016 May; 5(5):e317. PubMed ID: 27138177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of GalNAc
    Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
    Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
    Wang Y; Yu RZ; Henry S; Geary RS
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
    Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Assessment of Phase 2 Data on GalNAc
    Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
    Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.
    Shemesh CS; Yu RZ; Gaus HJ; Greenlee S; Post N; Schmidt K; Migawa MT; Seth PP; Zanardi TA; Prakash TP; Swayze EE; Henry SP; Wang Y
    Mol Ther Nucleic Acids; 2016 May; 5(5):e319. PubMed ID: 27164023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
    Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
    Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
    Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
    Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
    Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Metabolite Profiles of an
    Li XQ; Elebring M; Dahlén A; Weidolf L
    Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
    Geary RS; Bradley JD; Watanabe T; Kwon Y; Wedel M; van Lier JJ; VanVliet AA
    Clin Pharmacokinet; 2006; 45(8):789-801. PubMed ID: 16884318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.